Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review

Jiang, Shan; Chai, Huihui; Tang, Qisheng; Shi, Zhifeng; Zhou, Liangfu

doi:10.1007/s12672-023-00769-1

Cited by 5 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the standard of care, the mean overall survival period from diagnosis is less than 20 months. Moreover, the 5 year survival rate is only about 5.8% after standard of care treatment [ 16 ]. GBMs are highly diffusive and infiltrative in nature, often growing a few centimeters from the core, thus making it extremely difficult to achieve complete remission.…”

Section: Gliomas Glioblastoma Multiforme (Gbm) and The Promise Of Nan...mentioning

confidence: 99%

See 1 more Smart Citation

Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives

Lansangan,

Khoobchandani,

Jain

et al. 2024

Materials

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a glioma and the most aggressive type of brain tumor with a dismal average survival time, despite the standard of care. One promising alternative therapy is boron neutron capture therapy (BNCT), which is a noninvasive therapy for treating locally invasive malignant tumors, such as glioma. BNCT involves boron-10 isotope capturing neutrons to form boron-11, which then releases radiation directly into tumor cells with minimal damage to healthy tissues. This therapy lacks clinically approved targeted blood–brain-barrier-permeating delivery vehicles for the central nervous system (CNS) entry of therapeutic boron-10. Gold nanoparticles (GNPs) are selective and effective drug-delivery vehicles because of their desirable properties, facile synthesis, and biocompatibility. This review discusses biomedical/therapeutic applications of GNPs as a drug delivery vehicle, with an emphasis on their potential for carrying therapeutic drugs, imaging agents, and GBM-targeting antibodies/peptides for treating glioma. The constraints of GNP therapeutic efficacy and biosafety are discussed.

show abstract

Section: Gliomas Glioblastoma Multiforme (Gbm) and The Promise Of Nan...mentioning

confidence: 99%

“…Cancer encompasses a diverse group characterized by the uncontrolled growth and spread of abnormal cells [ 16 ]. It is pervasive and can affect nearly any tissue or organ in the body [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives

Lansangan,

Khoobchandani,

Jain

et al. 2024

Materials

View full text Add to dashboard Cite

show abstract

“…The second mechanism involves immunogenic cell death, which alarms immune cells by ejecting various particles, such as tumor antigens and damage-associated molecular patterns. Although this process needs further research, it holds promise in counteracting cancer and metastasis[ 149 ].…”

Section: Novel Cancer Therapiesmentioning

confidence: 99%

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Gromek,

Senkowska,

Płuciennik

et al. 2024

World J Methodol

View full text Add to dashboard Cite

In accordance with the World Health Organization data, cancer remains at the forefront of fatal diseases. An upward trend in cancer incidence and mortality has been observed globally, emphasizing that efforts in developing detection and treatment methods should continue. The diagnostic path typically begins with learning the medical history of a patient; this is followed by basic blood tests and imaging tests to indicate where cancer may be located to schedule a needle biopsy. Prompt initiation of diagnosis is crucial since delayed cancer detection entails higher costs of treatment and hospitalization. Thus, there is a need for novel cancer detection methods such as liquid biopsy, elastography, synthetic biosensors, fluorescence imaging, and reflectance confocal microscopy. Conventional therapeutic methods, although still common in clinical practice, pose many limitations and are unsatisfactory. Nowadays, there is a dynamic advancement of clinical research and the development of more precise and effective methods such as oncolytic virotherapy, exosome-based therapy, nanotechnology, dendritic cells, chimeric antigen receptors, immune checkpoint inhibitors, natural product-based therapy, tumor-treating fields, and photodynamic therapy. The present paper compares available data on conventional and modern methods of cancer detection and therapy to facilitate an understanding of this rapidly advancing field and its future directions. As evidenced, modern methods are not without drawbacks; there is still a need to develop new detection strategies and therapeutic approaches to improve sensitivity, specificity, safety, and efficacy. Nevertheless, an appropriate route has been taken, as confirmed by the approval of some modern methods by the Food and Drug Administration.

show abstract

“…Nevertheless, the recurrence rate remains high after treatment [10]. The average survival time for LGG patients is about ten years, while for HGG patients without treatment, this duration is less than 20 months [11], with only a small fraction of patients surviving more than three years after surgical treatment [12]. Therefore, understanding the underlying mechanisms of glioma development is crucial for identifying novel diagnostic biomarkers and potential therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas

Peng,

Chen,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Histone methyltransferase EZH2, primarily localized in the nucleus, mediates constitutive Polycomb repressive complex activity by trimethylating lysine 27 of histone H3 (H3K27me3), leading to gene silencing through canonical and noncanonical mechanisms, resulting in transcriptional repression or activation. Its involvement is crucial in cell growth, proliferation, differentiation, and apoptosis, with its effects linked to the regulation of various targets and signaling pathways. Overexpression of EZH2 alters gene expression and function, thereby facilitating cancer progression. Recent research has identified the potential prognostic role of EZH2 expression in glioma patients. This study assesses the clinicopathological significance and prognostic value of EZH2 expression in gliomas using available data. The mRNA levels of EZH2 in tumor tissues and normal tissues were assessed using timer2.0 and data from CGCA and TGCA. The prognostic significance of EZH2 mRNA expression was determined using Kaplan-Meier plotter. A total of 147 clinical samples from glioma patients underwent immunohistochemistry analysis to evaluate EZH2 protein expression. Cox proportional hazards regression model and Kaplan-Meier survival curves were employed to assess the relationship between EZH2 expression, clinicopathological parameters, and overall survival (OS). Across multiple tumor cohorts, EZH2 was found to be upregulated and amplified in tumor tissues. In high-grade glioma patients, EZH2 expression was significantly increased, and higher EZH2 expression correlated with poorer OS, disease-specific survival (DSS), and progression-free interval (PFI). Therefore, the level of EZH2 may serve as a prognostic biomarker for glioma patients.

show abstract

Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review

Cited by 5 publications

References 51 publications

Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives

Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas

Contact Info

Product

Resources

About